Kurt Reichen, VP Technical Operations at PaxVax, an American-headquartered fully integrated specialty vaccine company focused on infectious diseases, discusses the establishment of the company’s only site outside of the US in Bern, Switzerland, following the 2014 acquisition of a former Crucell manufacturing site from J&J.
The establishment of your Swiss site was a crucial step in PaxVax’s development as it enabled the company to have its first ever commercial vaccine on the market (Vivotif). Secondly, it provided PaxVax with a manufacturing facility in Thörishaus near Bern. Can you tell us more about the Swiss base today?
"PaxVax is basically a fully integrated company. We do everything from research and development, to commercial products, to the supply chain, and also to marketing sales."
